AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34260859 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer support program developed with a community‐based participatory action research (PAR) approach
Number of subjects: 100
Study 34260859 — intervention group
Group type: COMPARATOR
Intervention: Control group (delivery of information sessions)
Number of subjects: 100
Study 34260859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PAR and control)
Number of subjects: 100
Study 32092502 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band resistance training (EBRT) for 12 weeks, 3 times per week, progressively increasing resistance from yellow to red to black Thera-Band.
Number of subjects: 63
Study 32092502 — intervention group
Group type: COMPARATOR
Intervention: Control group received telephone contacts or face-to-face interviews weekly to maintain typical diet and activity habits.
Number of subjects: 63
Study 36336841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg every 3 weeks)
Number of subjects: 290
Study 36336841 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 290
Study 32988717 — intervention group
Group type: EXPERIMENTAL
Intervention: Field-in-field (FiF) technique
Number of subjects: 35
Study 32988717 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric arc radiation therapy (VMAT)
Number of subjects: 35
Study 32988717 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse intensity-modulated radiation therapy (IMRT)
Number of subjects: 35
Study 32988717 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicoidal therapy
Number of subjects: 35
Study 33547945 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (SCRT) followed by three cycles of consolidation chemotherapy with leucovorin, fluorouracil, and oxaliplatin (FOLFOX6)
Number of subjects: 19
Study 32493494 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200mg once daily for two months (HC group)
Number of subjects: 450
Study 32493494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 450
Study 34723164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat plus standard-of-care (SOC)
Number of subjects: 104
Study 34723164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat plus SOC
Number of subjects: 104
Study 34723164 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 104
Study 34723164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat
Number of subjects: 104
Study 33066756 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Number of subjects: 495
Study 34978932 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Health Activity Motor Program (CHAMP)
Number of subjects: 99
Study 34978932 — intervention group
Group type: COMPARATOR
Intervention: Control/Outdoor Free Play
Number of subjects: 99
Study 32703205 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support tools including decision aids, consultation cards, decision cards, and practical training for vascular surgeons.
Number of subjects: 502
Study 35021599 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib plus obinutuzumab
Number of subjects: 229
Study 35021599 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil plus obinutuzumab
Number of subjects: 229
Study 34215316 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (20 mg/day) with elemental calcium 1200 mg and vitamin D 800 IU daily
Number of subjects: 114
Study 34215316 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcium 1200 mg and vitamin D 800 IU only)
Number of subjects: 114
Study 34215316 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene group
Number of subjects: 114
Study 34215316 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 34939373 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day)
Number of subjects: 39
Study 34939373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 34499319 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational, expressional, and self-adjustment interventions
Number of subjects: 71
Study 34499319 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 71
Study 35733187 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL-FC teaching method
Number of subjects: 75
Study 35733187 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 75
Study 34339747 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition toward telomere attrition (one Z score decrease in length)
Number of subjects: 41935
Study 34339747 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic score for telomere attrition
Number of subjects: 41935
Study 34339747 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted kidney function decrease
Number of subjects: 41935
Study 32641163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 800 mg orally in two doses followed by 400 mg daily in two doses and azithromycin 500 mg orally in one dose followed by 250 mg in one dose for a total of 5 days (HC-A group)
Number of subjects: 0
Study 32641163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + placebo (HC group)
Number of subjects: 0
Study 32641163 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo (C-group)
Number of subjects: 0
Study 36333903 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom
Number of subjects: 104
Study 36333903 — intervention group
Group type: COMPARATOR
Intervention: Online-only instruction
Number of subjects: 104
Study 33641208 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival scaling
Number of subjects: 127
Study 33641208 — intervention group
Group type: COMPARATOR
Intervention: Moderate to high RA disease activity
Number of subjects: 127
Study 33641208 — intervention group
Group type: COMPARATOR
Intervention: Probing depth (PD)
Number of subjects: 127
Study 33641208 — intervention group
Group type: COMPARATOR
Intervention: Anti‐agalactosyl IgG titer
Number of subjects: 127
Study 32423941 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-module internet CBT programme
Number of subjects: 2500
Study 32423941 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 2500
Study 36303439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after lumbar fusion
Number of subjects: 62
Study 36303439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral fixation group (patients)
Number of subjects: 62
Study 36303439 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with adjacent segments degeneration (ASD)
Number of subjects: 62
Study 36303439 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 62
Study 33724684 — intervention group
Group type: EXPERIMENTAL
Intervention: Decomposition method from economics
Number of subjects: 0
Study 33724684 — intervention group
Group type: EXPERIMENTAL
Intervention: High dimensional balancing methods such as propensity score matching
Number of subjects: 0
Study 33724684 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching regime model
Number of subjects: 0
Study 32250503 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors/Angiotensin receptor blockers (ACEi/ARB)
Number of subjects: 56997
Study 32250503 — intervention group
Group type: COMPARATOR
Intervention: Beta blockers (BB)
Number of subjects: 56997
Study 36293938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 132
Study 36293938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 33879151 — intervention group
Group type: EXPERIMENTAL
Intervention: Unauthorized clinical trials for investigational products approved for marketing in Russia
Number of subjects: 26
Study 33879151 — intervention group
Group type: EXPERIMENTAL
Intervention: Unauthorized trials with mismatched therapeutic indications, posology, or administration method
Number of subjects: 26
Study 33879151 — intervention group
Group type: EXPERIMENTAL
Intervention: Unauthorized trial including a drug therapy intervention with an unapproved active substance
Number of subjects: 26
Study 33879151 — intervention group
Group type: EXPERIMENTAL
Intervention: Publications with advertisements for the medicinal product
Number of subjects: 26
Study 33879151 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims of efficacy in publications with advertisements
Number of subjects: 26
Study 33899214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg pre-operatively
Number of subjects: 79
Study 33899214 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-operatively
Number of subjects: 79
Study 32458778 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent antibiotic use
Number of subjects: 300
Study 32458778 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 300
Study 32458778 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 300
Study 32458778 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin
Number of subjects: 300
Study 32458778 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 300
Study 35678729 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes with nearly all risk factors within target ranges
Number of subjects: 715143
Study 35678729 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes with nearly optimal risk factor control
Number of subjects: 715143
Study 35678729 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 715143
Study 35678729 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 715143
Study 32151878 — intervention group
Group type: EXPERIMENTAL
Intervention: NC Gut Relief Formula (5 g/d for 4 weeks, then 10 g/d for 4 weeks)
Number of subjects: 43
Study 32151878 — intervention group
Group type: EXPERIMENTAL
Intervention: NC Gut Relief Formula
Number of subjects: 43
Study 34689170 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI/bevacizumab
Number of subjects: 324
Study 34689170 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX/bevacizumab
Number of subjects: 324
Study 34397196 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) foam, applied once daily for at least 4 weeks
Number of subjects: 164
Study 34397196 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam, applied once daily for at least 4 weeks
Number of subjects: 164
Study 32379535 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal retroflexion
Number of subjects: 692
Study 32379535 — intervention group
Group type: COMPARATOR
Intervention: Second forward view
Number of subjects: 692
Study 35666250 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) program, 10 sessions
Number of subjects: 226
Study 32546726 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 at 50 units/m2
Number of subjects: 56
Study 32546726 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 at 75 units/m2
Number of subjects: 56
Study 32546726 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 at 100 units/m2
Number of subjects: 56
Study 32546726 — intervention group
Group type: COMPARATOR
Intervention: Control (standard chemotherapy)
Number of subjects: 56
Study 36288590 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated high‐voltage long‐duration PRF (group R)
Number of subjects: 81
Study 36288590 — intervention group
Group type: COMPARATOR
Intervention: Standard voltage PRF (group S)
Number of subjects: 81
Study 36288590 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐voltage long‐duration PRF (group H)
Number of subjects: 81
Study 33827786 — intervention group
Group type: EXPERIMENTAL
Intervention: MyChildCMC
Number of subjects: 50
Study 33827786 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 35276778 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin Boswellia Phytosome (CBP) and Low FODMAP diet (LFD) - 500 mg bid of CBP and LFD for 30 days
Number of subjects: 67
Study 35276778 — intervention group
Group type: COMPARATOR
Intervention: Low FODMAP diet (LFD)
Number of subjects: 67
Study 35276778 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin Boswellia Phytosome (CBP) and Low FODMAP diet (LFD)
Number of subjects: 67
Study 34060339 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile traction therapy
Number of subjects: 82
Study 34060339 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 82
Study 35064853 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesix™ mesh
Number of subjects: 270
Study 35064853 — intervention group
Group type: COMPARATOR
Intervention: Progrip™ mesh
Number of subjects: 270
Study 33403699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Number of subjects: 0
Study 33403699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 0
Study 34134877 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent SMART + TAU
Number of subjects: 61
Study 34134877 — intervention group
Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 61
Study 32283854 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates program under hypoxic conditions (H trial)
Number of subjects: 10
Study 32283854 — intervention group
Group type: COMPARATOR
Intervention: Pilates program under normoxic conditions (N trial)
Number of subjects: 10
Study 35667569 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly pegcetacoplan treatment (AM)
Number of subjects: 246
Study 35667569 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly pegcetacoplan treatment (AEOM)
Number of subjects: 246
Study 35667569 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (SM)
Number of subjects: 246
Study 34449946 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification treatment + 5?M of Retinol
Number of subjects: 0
Study 34449946 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification treatment
Number of subjects: 0
Study 34449946 — intervention group
Group type: COMPARATOR
Intervention: Control fresh preantral follicles
Number of subjects: 0
Study 36369901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 48
Study 36369901 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 48
Study 34438218 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural stability measures (MiniBEST test)
Number of subjects: 41
Study 34438218 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural sway area on a firm surface
Number of subjects: 41
Study 34438218 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze stability measures (horizontal and vertical VOR gain)
Number of subjects: 41
Study 34438218 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze stability outcomes (DHI score)
Number of subjects: 41
Study 32580977 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced self-management (digital home monitoring with centralised specialist support)
Number of subjects: 202
Study 32580977 — intervention group
Group type: COMPARATOR
Intervention: Supported medical management (digital home monitoring alone)
Number of subjects: 202
Study 32580977 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced self-management
Number of subjects: 202
Study 35851518 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of Botulinum toxin A injection
Number of subjects: 24
Study 35851518 — intervention group
Group type: COMPARATOR
Intervention: Multiple sessions of multivitamins mesotherapy injection
Number of subjects: 24
Study 33318152 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted higher SHBG in men
Number of subjects: 179916
Study 33318152 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted higher SHBG in men (multivariable MR controlling for testosterone)
Number of subjects: 179916
Study 33318152 — intervention group
Group type: COMPARATOR
Intervention: Genetically predicted higher SHBG in women
Number of subjects: 179916
Study 36443174 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg then 25 mg x 5 doses)
Number of subjects: 43
Study 36443174 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin (A1AT) (90 mg/kg x 6 doses)
Number of subjects: 43
Study 36443174 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 43
Study 33819452 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, high-calorie oral nutritional supplements (ONS), 2 bottles daily for 3 months
Number of subjects: 282
Study 33210468 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study 33210468 — intervention group
Group type: COMPARATOR
Intervention: Control immunisations (PCV13 and DTaP-IPV-Hib) without 4CMenB
Number of subjects: 0
Study 33210468 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant regimen (4CMenB with control immunisations)
Number of subjects: 0
Study 35920293 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat peptides (WP)
Number of subjects: 49
Study 35920293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 49
Study 35643076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA) supplementation: 2g intravenously during induction of anesthesia, 2g before aortic cross-clamp removal, and 1g every 8 hours for five postoperative days.
Number of subjects: 332
Study 35643076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AA supplementation).
Number of subjects: 332
Study 35643076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA) supplementation.
Number of subjects: 332
Study 33685706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedated: lidocaine cornual nerve block, 0.5 mg/kg meloxicam (subcutaneously), and 0.2 mg/kg xylazine (intramuscularly)
Number of subjects: 122
Study 33685706 — intervention group
Group type: COMPARATOR
Intervention: Nonsedated: lidocaine cornual nerve block and meloxicam
Number of subjects: 122
Study 32800315 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 18
Study 32800315 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 18
Study 33184647 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified (yellow) cassava
Number of subjects: 176
Study 33184647 — intervention group
Group type: COMPARATOR
Intervention: White cassava (control)
Number of subjects: 176
Study 32195639 — intervention group
Group type: EXPERIMENTAL
Intervention: 445-nm diode laser irradiation on metallic brackets for 15 seconds before debonding
Number of subjects: 70
Study 32195639 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 70
Study 32195639 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser group (445-nm diode laser treatment)
Number of subjects: 70
Study 34302745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg daily orally)
Number of subjects: 1250
Study 34302745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250
Study 32791501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) and Well-Being Therapy (WBT)
Number of subjects: 100
Study 32791501 — intervention group
Group type: COMPARATOR
Intervention: Clinical Management (CM)
Number of subjects: 100
Study 34362323 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified online HIV report with exchange mechanism
Number of subjects: 0
Study 34362323 — intervention group
Group type: COMPARATOR
Intervention: Without exchange mechanism
Number of subjects: 0
Study 36475325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubertal and menstrual health education intervention (seven 2-hour educational sessions)
Number of subjects: 578
Study 36475325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 578
Study 33571736 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib and cetuximab (arm A)
Number of subjects: 125
Study 33571736 — intervention group
Group type: COMPARATOR
Intervention: Placebo and cetuximab (arm B)
Number of subjects: 125
Study 32870276 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral wrist splint for 6 weeks (group A)
Number of subjects: 30
Study 32870276 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral wrist splint for 12 weeks (group B)
Number of subjects: 30
Study 35034653 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral intermittent theta burst stimulation (piTBS) applied directly to spastic muscles, 8 sessions with supra threshold intensity
Number of subjects: 36
Study 35034653 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study 32414414 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiao-tai-wan (JTW)
Number of subjects: 124
Study 32414414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 34116270 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced ovarian failure (CIOF) after anthracycline/taxane-based chemotherapy
Number of subjects: 696
Study 34116270 — intervention group
Group type: EXPERIMENTAL
Intervention: Regain of premenopausal hormone levels after chemotherapy
Number of subjects: 696
Study 34116270 — intervention group
Group type: COMPARATOR
Intervention: Disease-free survival (DFS) without CIOF
Number of subjects: 696
Study 34116270 — intervention group
Group type: COMPARATOR
Intervention: Disease-free survival (DFS) in hormone receptor positive patients
Number of subjects: 696
Study 34116270 — intervention group
Group type: COMPARATOR
Intervention: Disease-free survival (DFS) in patients aged <30 years
Number of subjects: 696
Study 32147076 — intervention group
Group type: EXPERIMENTAL
Intervention: Green coffee extract (GCE) 400 mg daily for 8 weeks
Number of subjects: 48
Study 32147076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 35301381 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 120
Study 35301381 — intervention group
Group type: COMPARATOR
Intervention: Desflurane inhalation anesthesia
Number of subjects: 120
Study 32990215 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (370 subjects)
Number of subjects: 496
Study 32990215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (126 subjects)
Number of subjects: 496